Paroxysmal Atrial Fibrillation Clinical Trial
— CATS-AFOfficial title:
Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation.
Atrial The treatment of atrial fibrillation (AF) includes 2 axes: the prevention of the cardio-embolic risk and rhythm control. The possibilities for this control are antiarrhythmic drugs and, above all, catheter ablation, an interventional cardiology technique which consists in treating the areas responsible for the initiation and perpetuation of AF by applying radiofrequency energy or cryotherapy to the myocardial tissue. Limited research has been done on the combination of different parameters to manage AF, especially during the initial stage of the disease. A translational and multimodal approach could make it possible to better characterize this pathology and thus, help to adjust the therapeutic management for the patients. The combined analysis of regional electrophysiological, morphological, and functional parameters of the left atrium could make it possible to better detect early atrial cardiomyopathy and predict recurrences of atrial fibrillation.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | November 2025 |
Est. primary completion date | November 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Patient aged 18 to 60 years 2. Established diagnosis of paroxysmal or persistent symptomatic atrial fibrillation (AF) for at least 3 months with indication of catheter ablation 3. AF episode documented by ECG in the last 12 months 4. Structurally healthy heart, with an LVEF> 50%, an interventricular septum <12 mm and an OG volume <40mL / m ² by TTE 5. Having given their informed consent in writing 6. Affiliated with or entitled to a French social security scheme Exclusion Criteria: 1. Mitral valve disease with grade 2 to 4 insufficiency 2. Heart failure (NYHA stage II to IV in sinus rhythm and LVEF < 50%), hypertrophic heart disease or congenital heart disease 3. Contraindication to oral anticoagulation 4. Intracardiac thrombus 5. History of ablation of the left atrium 6. History of heart surgery 7. Contraindication to performing MRI or using the DOTAREM™ contrast medium (pacemaker, defibrillator, prosthesis, old generation heart valves, old generation ferromagnetic vascular surgical clips, treatment type endocranial aneurysms, neurosimulator, cochlear implants, automated injection device such as insulin pump, and more generally any non-removable electronic medical device or equipment, kidney disease with GFR < 30 mL/min, hypersensitivity to gadoteric acid or to excipients) 8. History of myocardial infarction or coronary angioplasty within the last three months 9. Chronic obstructive pulmonary disease 10. Under guardianship or curatorship 11. Women who are pregnant, breastfeeding or of childbearing age in the absence of effective contraception 12. Participation in another interventional research involving a health product |
Country | Name | City | State |
---|---|---|---|
France | Institut de Cardiologie de la Pitié-Salpêtrière | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Correlation between the regional and global longitudinal strain peaks (percent (%)) and voltage (millivoltage(mV)) of the left atrium measured by MRI and catheter ablation | 1 month | ||
Secondary | Localization in the left atrium and area of low amplitude electrogram areas (<0.5 mV, <0.3 mV and <0.1 mV) measured during the ablation procedure | 1 month | ||
Secondary | Localization in the left atrium and areas of fragmented atrial complexes measured during the ablation procedure | 1 months | ||
Secondary | Local atrial impedance measured by ablation catheter | 1 months | ||
Secondary | Contact force measured by ablation catheter | 1 month | ||
Secondary | Local impedance drop measured during radiofrequency delivery | 1 month | ||
Secondary | Duration of the ablation for each radiofrequency delivery | 1 month | ||
Secondary | Localization of the segmental and regional alteration of the myocardium in the left atrium measured during MRI | 3 months | ||
Secondary | Localization of zones with impaired 4D flow in the left atrium measured during MRI | 3 months | ||
Secondary | Left atrium volume (milliliter (mL)) measured during MRI | 3 months | ||
Secondary | Localization of areas of late enhancement in the left atrium | 3 months | ||
Secondary | Lesion transmurality performed by ablation in each segment of the pulmonary veins | 3 months | ||
Secondary | Subcutaneous measurement (AGE Reader) which combines aging and accumulation of glycated proteins in the subcutaneous tissue measured during MRI | 3 months | ||
Secondary | Volumes (milliliter (ml)) of the left atrium: in the basal state and after passive filling measured during echocardiography | 1 month | ||
Secondary | Analysis of the longitudinal deformation (strain) in speckle tracking in the basal state and after passive measured during echocardiography | 1 month | ||
Secondary | Absence of atrial fibrillation occurrence | 12 months | ||
Secondary | Absence of persistent atrial fibrillation occurrence | 12 months | ||
Secondary | Absence of atrial tachycardia or atrial flutter occurrence after catheter ablation | 12 months | ||
Secondary | Absence of palpitation occurrence after catheter ablation | 12 months | ||
Secondary | 6-minute walking test to assess exercise capacity | 1 month | ||
Secondary | Differences in the volumes (milliliter (ml)) of the left atrium (maximum, minimum, atrial pre-systole) between the segmentation performed manually and the segmentation obtained by learning transfer | 3 months | ||
Secondary | Distance between areas of low voltages identified by the cartography and areas of late 3D enhancement identified by MRI, measurement based on the volume (milliliter (ml)) resulting from CT-scan and MRI fusion | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05970120 -
A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
|
N/A | |
Recruiting |
NCT06014996 -
Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation.
|
N/A | |
Completed |
NCT03624881 -
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
|
Phase 4 | |
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Recruiting |
NCT05905835 -
Treatment of PAF With the Synaptic System
|
N/A | |
Active, not recruiting |
NCT05534581 -
SINGLE SHOT CHAMPION
|
Phase 4 | |
Active, not recruiting |
NCT05618340 -
PFA for Paroxysmal Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT05024630 -
Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension
|
N/A | |
Completed |
NCT01913522 -
Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration
|
N/A | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Terminated |
NCT01925885 -
Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)
|
N/A | |
Withdrawn |
NCT01917981 -
Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation
|
Phase 3 | |
Completed |
NCT01842529 -
Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery
|
Phase 2 | |
Completed |
NCT01693107 -
Atrial Fibrillation Force Contact Ablation Study
|
||
Completed |
NCT00971204 -
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT05043883 -
Automated Assessment of PVI Using a Novel EP Recording System
|
N/A | |
Recruiting |
NCT05172765 -
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
|
N/A | |
Recruiting |
NCT04529785 -
Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation
|
N/A | |
Completed |
NCT04022954 -
HD Mapping of Atrial Fibrillation in Asia Pacific
|
||
Completed |
NCT00964392 -
NAVISTAR® THERMOCOOL® Catheter Post Approval Registry
|
Phase 4 |